Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite initiates preclinical studies of its two lead drug candidates

Apr. 20, 2021 8:36 AM ETCan-Fite BioPharma Ltd. (CANF)
By: Aakash Babu, SA News Editor

Can-Fite BioPharma (NYSEMKT:CANF) announces that it has initiated a series of preclinical studies required by health regulators for the marketing applications of the company's psoriasis and liver cancer treatments.

The company's piclidenoson treatment is in late-stage development for Psoriasis, while namodenoson is set to enter pivotal phase III trial for liver cancer.

As part of a New Drug Application (NDA) to the U.S. FDA and a Marketing Authorization Application to the EMA, both agencies require certain preclinical data be submitted along with the pivotal Phase III data.

The pivotal phase III study of namodenoson in the treatment of hepatocellular cancer (HCC), the most common form of liver cancer, is expected to commence in the fourth quarter of 2021.